--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...

THOUSAND OAKS, Calif., June 1, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from a randomized, double-blind, placebo-controlled, multicenter Phase 3 study evaluating the treatment ...

Amgen (NASDAQ:AMGN) announced new data supporting its FDA-approved osteoporosis therapy Prolia (Denosumab) on Monday, highlighting its potential against oral alendronate, a commonly-used medication to ...

THOUSAND OAKS, Calif., May 8, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S.

Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and in men at high risk for fracture ...

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...

THOUSAND OAKS, Calif., June 8, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication for Prolia ® (denosumab) for the treatment of ...

New 2-Year Open-Label Study Shows More Than 90 Percent of Patients Preferred Prolia Injection Every Six Months Over Weekly Oral Alendronate THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen ...

Osteoporosis (OP) is the most common multifactorial metabolic bone disorder worldwide, and is a major public health concern among the elderly and in postmenopausal women. It is therefore of global ...

Prolia should be covered by Medicare Part A, Part B, or Part D, depending on why you need to take the drug and whether you will administer it yourself. Prolia (denosumab) is an injectable monoclonal ...

Dr. Reddy’s and Alvotech have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to Prolia and Xgeva (denosumab). The collaboration ...